Investment Pitches

Pitch Summary:
Advanced Micro Devices, Inc. (AMD) reported strong Q4 2025 results, with revenue reaching $10.3 billion, a 34% increase year-over-year, and surpassing estimates by $630 million. The company's data center segment was a standout, with revenue up 39% year-over-year, driven by strong sales of EPYC processors and Instinct GPUs. The client and gaming segments also showed significant growth, with gaming revenue rebounding by 50% year-over-year. AMD's gross margins exceeded expectations, reaching 57%, and operating margins improved significantly. Despite increased operating expenses, the company achieved a 41% increase in adjusted operating income year-over-year. The strong performance and positive outlook suggest that AMD's valuation will continue to grow, making any short-term weakness in shares a buying opportunity.

BSD Analysis:
AMD's Q4 performance highlights its strength in the semiconductor industry, particularly in the data center and gaming segments. The company's ability to exceed revenue and margin expectations demonstrates its operational efficiency and market demand for its products. The secular growth in AI-related demand further supports AMD's long-term prospects, as its products are well-positioned to capitalize on this trend. Despite potential headwinds from increased competition and market volatility, AMD's robust financial performance and strategic positioning suggest continued growth. The company's manageable debt levels and strong cash flow provide additional financial flexibility to invest in future growth opportunities. Investors should consider AMD's strong fundamentals and growth potential when evaluating their investment strategy.

Pitch Summary:
Prudential Financial, Inc. has shown resilience despite recent challenges, with a focus on capital returns and steady improvements in its financials. The company has a strong balance sheet with $3.8 billion in liquid assets, supporting its dividend and buyback programs. Prudential's dividend yield of approximately 5% is secure, backed by 18 consecutive years of dividend increases. The company is expected to earn between $14.30 and $14.90 in 2026, with a significant portion of earnings returned to shareholders. Prudential's shares are trading at an attractive 8% capital return yield, and the stock is expected to provide a 10+% total return in 2026.

BSD Analysis:
Prudential's U.S. operations have shown solid performance, with increased earnings driven by higher net investment spreads and favorable underwriting outcomes. The company's asset management arm, PGIM, faces challenges with outflows, but its competitive product set remains strong. Internationally, Prudential's Japanese operations face temporary setbacks due to regulatory issues, but the financial impact is expected to be limited. The company's conservative investment portfolio, with a focus on private credit, is well-managed, and the risk of credit losses is minimal. Overall, Prudential's financial strength and strategic focus on capital returns make it an attractive option for income-oriented investors.

Pitch Summary:
Novo Nordisk's recent approval of the oral Wegovy pill marks a significant shift in its product strategy. However, the transition from injectable to oral GLP-1 drugs is expected to severely impact the company's margins. The oral version requires a much higher dosage due to poor gastrointestinal absorption, leading to increased production costs. Additionally, the new pricing strategy, driven by regulatory pressures, significantly lowers the revenue per unit compared to the injectable form. The company's recent earnings report showed a decline in margins and a negative sales outlook for 2026, further supporting the bearish outlook.

BSD Analysis:
The shift to oral Wegovy is a strategic move that comes with substantial financial challenges. The increased dosage requirement for the oral form results in a 70x increase in active pharmaceutical ingredient (API) usage, which is costly. This, combined with the reduced pricing, leads to a dramatic drop in gross margins from over 90% for injectables to around 35% for the oral version. The company's guidance for 2026 indicates a potential decline in sales and operating profits, reflecting the unsustainable economics of the oral strategy. The rapid uptake of the oral pill is cannibalizing the higher-margin injectable sales, further eroding profitability.

Pitch Summary:
ArcBest Corporation (ARCB) is positioned for a strong recovery as it exits the trough of the freight cycle. Despite a decline in headline revenue, the company is experiencing market share gains and volume growth, indicating underlying demand strength. The asset-based segment shows positive volume trends, with tonnage and daily shipments increasing year-over-year. The company's focus on cost discipline is evident in its improved operating ratios, and the mix shift towards heavier freight is enhancing efficiency. As volume density improves, ArcBest is expected to benefit from significant operating leverage, leading to a sharp recovery in earnings. With consensus not fully pricing in this recovery, there is substantial upside potential if current volume momentum continues.

BSD Analysis:
ArcBest's recent performance suggests it is overcoming the challenges of the freight downcycle. The company's ability to increase shipment volumes, despite a weak macroeconomic backdrop, highlights its competitive positioning and customer preference. The mix shift towards heavier freight, while impacting revenue per hundredweight, is actually beneficial for operational efficiency, reducing touchpoints and improving margins. The market's conservative expectations for ArcBest's future earnings provide an opportunity for upside as the company continues to recover. If ArcBest can maintain its volume growth and improve profitability in its asset-light segment, it could achieve its ambitious EPS targets, leading to a potential re-rating of its stock.

Pitch Summary:
ServiceNow is a mission-critical enterprise software company with a deeply integrated workflow platform that drives high switching costs and strong pricing power. Despite a recent 33% drop in share price, the company's fundamentals remain robust, with 20%+ revenue growth, 98% customer retention, and best-in-class free cash flow generation. The sell-off is attributed to broader industry trends and misconceptions about AI's impact on SaaS, not company-specific issues. ServiceNow is well-positioned to benefit from AI, potentially becoming the default AI orchestration layer for enterprises, offering a generational growth opportunity. The current sentiment-driven discount presents a compelling opportunity to acquire shares in a high-quality compounder with a massive runway for growth.

BSD Analysis:
ServiceNow's Q4 2025 results exceeded expectations, with strong top-line and bottom-line performance, highlighting its resilience and growth potential. The company's platform innovation and customer acquisition strategies continue to drive growth, with significant adoption of AI modules like Now Assist. ServiceNow's recent M&A activity, including acquisitions of cybersecurity firms Veza and Armis, aims to strengthen its platform and expand its TAM, not compensate for a lack of organic growth. The company's valuation appears exceptionally cheap, trading at a significant discount to historical averages, providing a rare opportunity for investors to acquire a best-in-class enterprise software company at an attractive price.

Pitch Summary:
Marco Polo Marine (+217% in 2025, ~15% contribution to overall portfolio gains). We first began following Marco Polo Marine at a time when the offshore and marine sector was deeply shaken by the post-2014 downturn. The key inflection point came in 2017 when Penguin International emerged as a strategic white knight investor, strengthening governance and capital discipline. Our thesis evolved from a cyclical recovery opportunity to a structural compounding setup as MPM repositioned toward offshore wind vessels and higher-value ship repair. It secured a three-year master service agreement with Cyan Renewables and expanded into specialised offshore wind-linked vessels and research vessels. Revenue drivers shifted toward secular growth industries with better earnings visibility. We were effectively able to invest at near-distressed valuations and hold through both cyclical recovery and business transformation. The market has begun to re-rate MPM from single-digit P/E to mid-teens multiple as earnings quality improved. We intend to remain patient long-term shareholders. :contentReference[oaicite:5]{index=5}

BSD Analysis:
Marco Polo Marine is navigating a period of significant revenue expansion, with annual growth forecast at nearly eighteen percent as it capitalizes on the regional offshore wind and marine infrastructure boom. While earnings per share are undergoing a temporary reset following a record-breaking 2025, the company’s strategic re-composition of its board and committees signals a move toward more institutionalized governance. Management has demonstrated a commitment to shareholders by increasing dividends, supported by a balance sheet that has significantly improved through disciplined debt management. The company’s focus on high-utilization chartering services in Southeast Asia provides a stable recurring revenue base that offsets the cyclicality of the broader shipping industry. As regional demand for marine logistics in the renewable energy sector continues to scale, Marco Polo Marine remains a high-growth small-cap play on the green energy transition.

Pitch Summary:
KKR was down -13.3% in 2025 after starting the year at elevated valuations (25x PE). Industry concerns around private equity exits and private credit defaults weighed on sentiment. However, as of 3Q2025, over the last twelve months, KKR’s AUM, management fees and fee-related earnings have grown 15.8%, 16.3% and 15.6%, respectively. We believe volatility provided an opportunity and added at reasonable valuations. We expect AUM, fees and earnings to continue compounding over many years. :contentReference[oaicite:4]{index=4}

BSD Analysis:
KKR is on track to exceed its ambitious fundraising goals, targeting over 300 billion dollars in new capital as it scales its diversified platform across private equity, infrastructure, and credit. The company’s 2026 outlook is underpinned by a target of seven dollars per share in adjusted net income, supported by a significant recovery in M&A and IPO activity. A key driver of recent growth is the strategic acquisition of Arctos, which positions KKR as a global leader in the rapidly professionalizing sports asset class. Management has demonstrated exceptional operational leverage, growing management fees by fifty percent over the past three years while keeping expense growth strictly limited. With nearly 19 billion dollars in embedded gains across its portfolio, KKR is well-positioned to deliver outsized returns to shareholders as monetization cycles accelerate throughout the year.

Pitch Summary:
In 2025, both stocks were down for the year — APO -11.1%. After a strong run in 2023-2024, where share prices ran up much faster than earnings, the company started the year at what we believe were high valuations — APO at 19x PE. Even as earnings continued to grow in 2025, valuations came down more due to industry-specific concerns around private equity fundraising and private credit risks. Despite negative headlines, underlying fundamentals continue to perform. As of 3Q2025, over the last twelve months, APO’s AUM, management fees and fee-related earnings have grown 23.9%, 19.6% and 21.7%, respectively. We were glad to add to our positions at what we believe to be reasonable valuations. We continue to see tailwinds in alternative assets and believe APO is well-positioned to compound AUM, fees and earnings for many years. :contentReference[oaicite:3]{index=3}

BSD Analysis:
Apollo Global Management is capitalizing on a "K-shaped" economy, leveraging its industry-leading origination platforms to capture high-quality, investment-grade private credit opportunities. The firm recently reported record fee-related earnings growth of 23 percent, driven by a massive expansion in its wealth management platform and third-party insurance mandates. In 2026, Apollo expects to achieve a significant expansion in its FRE margins as it scales its Atlas origination business and launches new products for the private wealth channel. Management’s focus on the convergence of asset management and retirement services through Athene provides a steady, uncorrelated source of capital that differentiates it from pure-play private equity firms. As institutional demand for private credit continues to surge, Apollo’s scale and disciplined underwriting position it for sustained double-digit earnings growth.

Pitch Summary:
TSMC continues to perform well beyond our expectations. In 2025, revenue grew by 36% in USD, largely driven by AI-related demand. Even more impressive was the improvement in gross margin, a result of TSMC’s excellent cost improvement efforts and higher capacity utilization rate due to strong demand for their chips. Coupled with operating leverage, earnings per share increased by 46.4%. ROE also increased from 30.3% in 2024 to 35.4% in 2025. During their most recent earnings call, management guided for another ~30% increase in revenue in USD in 2026 and revised up their 5-year revenue CAGR guidance (2024 to 2029) from ~20% to ~25%. We could not be more impressed with the continued strong execution from TSMC’s management team. These results are a function of what TSMC calls their Trinity of Strengths: Technology Leadership, Manufacturing Excellence and Customer Trust. A key risk is whether there is an AI bubble, especially given TSMC’s plans to spend up to US$56 billion in capital expenditures in 2026. These investments will allow TSMC to manufacture more chips in 2028/2029 — it takes time for these giant facilities to be built and to be ready for production. But if demand were to taper off, the newly built capacity may be underutilized, which will significantly impact TSMC’s profits. In response, management has been verifying demand with customers and cloud providers before committing such big investments. TSMC is one of the most important semiconductor companies in the world, and we continue to believe that their Trinity of Strengths positions them well for sustained success in an increasingly high computing era. :contentReference[oaicite:1]{index=1}

BSD Analysis:
TSMC enters 2026 with an unprecedented revenue growth forecast of nearly thirty percent, fueled by insatiable global demand for advanced AI and high-performance computing chips. As the sole manufacturer of the world’s most sophisticated logic chips for Apple and NVIDIA, the company holds a near-monopoly position at the leading edge of the 2-nanometer and 3-nanometer nodes. Management’s revised long-term guidance points to a 25 percent compound annual growth rate through 2029, a remarkable feat for a company of its massive scale. Despite geopolitical tensions, TSMC’s expansion of manufacturing capacity in the United States and Japan is diversifying its operational risk and securing its role in the global supply chain. Trading at a discount to many of its big tech customers, the stock remains one of the most compelling value propositions in the entire technology sector.

Pitch Summary:
Our fourth quarter gains were driven primarily by our investment in D-BOX Technologies (“D-BOX”), a Canadian-based micro-cap company which became a material holding during the second half of 2025. In December 2025, we shared an investment memorandum detailing our thoughts on D-BOX. D-BOX is a position we continue to own with conviction. We were fortunate to find and build a significant position in D-BOX last year, which experienced a triple-digit percentage share price gain in 2025 and accounted for a meaningful share of our performance.

BSD Analysis:
D-BOX Technologies is experiencing a record-setting 2026, with royalty revenues and net profits reaching all-time highs as its haptic technology gains theatrical traction. The company’s screen footprint is expanding globally, driven by a growing network of exhibitor circuits that see immersive experiences as a critical differentiator for cinemas. Theatrical system sales recently surged by over 60%, positioning the firm with a solid sales pipeline in North America and Latin America. Management has successfully achieved debt-free status, allowing D-BOX to capitalize fully on its high-margin royalty-focused model. While simulation and sim racing markets have remained flat, the theatrical ecosystem is providing more than enough momentum to drive double-digit total revenue growth. D-BOX is proving to be a resilient player in the entertainment tech space, successfully decoupling its performance from broader box office volatility.

Pitch Summary:
One of those is that I have been ramping up non CRE investments, an interesting example of which is uniQure. This is a biotech stock which has a potential groundbreaking gene therapy for Huntington’s disease called AMT-130. They presented their initial results back in September which showed disease progression slowing by ~75% 3 years after treatment, and the stock rocketed up to as high as $70/share. In a twist, the FDA came in 2 months later and rescinded their previous agreement to use an external matched control group to compare Qure’s treatment to, which has caused the stock to crash down to its current price of ~$23/share. What is interesting here to me is that very few argue that the drug isn’t effective – the worst case scenario seems to be that the FDA makes Qure do a randomized phase 3 control study. Qure has a significant amount of cash on hand (~$700mm as of Q3, relative to its ~$200mm/year burn rate), and could fund a trial if they had to worst case. Ultimately, if the therapy works, and we should know this with a very high degree of certainty by August, it is really hard for me to imagine this treatment not getting approved. There is some risk here, but the balance of upside vs downside feels very favorable to me.

BSD Analysis:
uniQure is approaching a critical clinical inflection point in early 2026, with major data readouts expected for its Fabry disease and Huntington’s disease programs in the first half of the year. The company’s 2026 investment thesis is anchored by a strong cash position of $694 million, providing a financial runway that extends into 2029. Recent clinical results for its Huntington’s program (AMT-130) showed a statistically significant 75% slowing in disease progression, a major milestone that has significantly de-risked the platform. For 2026, the primary catalyst remains the potential for regulatory milestones that could unlock an additional $100 million in term loans. While the stock remains in a high-risk R&D phase, the refinancing of its debt to extend the term to 2030 and the successful upsized public offering in late 2025 have provided the stability needed to execute its clinical pipeline. For biotech-focused investors, the H1 2026 updates will be the ultimate signal for the company’s transition toward commercial-stage gene therapy.

Pitch Summary:
Unfortunately the software firm I am short, Palantir, has surprisingly not fallen very much despite being massively more highly valued than any other software firm. Perhaps I should have taken a broader basket, but I remain convinced that Palantir has a lot of potential downside given its rich valuation. And it is especially nice as a hedge against a downturn.

BSD Analysis:
Palantir enters 2026 as a foundational player in the "Sovereign AI" market, having recently secured key roles in EMEA data center infrastructure and a group-wide AI expansion with HD Hyundai. The stock remains a high-growth favorite, up 77.7% over the past year, as the company successfully moves beyond its specialized government roots into large-scale industrial AI deployments. For 2026, the investment case is centered on the rapid adoption of its AIP (Artificial Intelligence Platform), which is being embedded in mission-critical shipbuilding, robotics, and logistics workloads. While recent pullbacks in early 2026 have created short-term volatility, the long-term trend remains positive as the firm shifts its revenue mix toward high-margin commercial contracts. Management’s focus on "national-security grade" software allows it to maintain significant pricing power in an increasingly crowded enterprise AI field. As Palantir scales its EMEA sovereign footprint, investors are closely watching for continued acceleration in commercial customer acquisition as the primary driver for a valuation re-rating.

Pitch Summary:
Alexandria is another – in attempting to catch a falling knife, I didn’t quite time the bottom right, but I still believe we have a very attractive basis, and the stock looks even better today. ARE is the largest life sciences landlord in the US – this sector has struggled with a double whammy of a biotech bust and big oversupply (triple if you want to count WFH, though lab space wasn’t hit quite as hard as normal office in this regard). I believe the stock is currently oversold – their portfolio is by far the highest quality with some truly top tier assets. The bio sector is coming back, and I believe strongly in its long term growth. In fact it began to recover somewhat in 2025, just take a look at the XBI. The stock market is a leading indicator, real estate leasing is very lagging, and we should see a turnaround in bio leasing fundamentals in the next year or two. ARE is trading at an ~10%+ cap rate today, which I believe falls to low 9s on future NOI declines – too cheap given the strong lease terms & asset quality.

BSD Analysis:
Alexandria Real Estate Equities is undergoing a strategic "asset recycling" phase in 2026, recently updating its FFO guidance to a range of $6.25 to $6.85 per share. The company’s 2026 outlook is currently challenged by declining occupancy rates, though it remains the gold standard for life science and laboratory real estate. For the current year, the primary catalyst is the expected closure of $1 billion in asset dispositions, which will provide the liquidity needed to fund its robust development pipeline. Despite short-term pressures, the sector saw a 2.89% gain in early 2026, outperforming the broader market as tech-related selloffs drove rotation into high-quality REITs. Management’s focus on "mega-campus" clusters in top-tier markets like Boston and San Francisco provides a significant competitive moat against traditional commercial office space. For value-oriented investors, the current discount to historical multiples offers an entry point into a REIT with a mission-critical tenant base and a proven long-term track record of dividend growth.

Pitch Summary:
McDermott is now a core position for the fund. The company is working to refinance its debt, resume SEC reporting, and return its shares to a major exchange. Operating trends are improving, with 2025 adjusted EBITDA expected to exceed $400 million, up more than 70% year-over-year. McDermott has secured billions in new contracts for Middle Eastern national oil companies and energy transition projects. If execution continues and margins improve, I see upside to $60 or higher versus current trading in the mid-$20s.

BSD Analysis:
McDermott International is execution risk wrapped in hard-asset relevance, which is exactly why it never screens cleanly. The company sits in offshore energy and infrastructure projects where budgets are massive and mistakes are unforgiving. Its history of overreach and restructuring still dominates perception, but the reset changed incentives toward discipline, not growth-at-any-cost. Demand for complex energy infrastructure hasn’t disappeared; it just shifted toward fewer contractors willing to take it on. Backlog quality and contract structure matter more than headline revenue here. Investors underestimate how scarce true offshore engineering capability has become after years of capital flight. When projects go right, operating leverage is violent. When they go wrong, equity gets punished fast. This is not a comfort stock — it’s a cyclical execution bet on energy infrastructure scarcity.

Pitch Summary:
Our new largest position, Vail Resorts, is probably the best example of this. I started buying in February, when the stock was in the upper $150s. Unfortunately the stock is now trading at $133 (which I think is an incredible opportunity on the flip side) – I bought more as it fell, but our cost basis is around ~$148, so we are still down a decent bit here. Vail deserves its own write up entirely, but the quick thesis on it is that Vail owns irreplaceable assets with very limited new competition, and is cheap on almost any metric you want to use. For context the first new ski resort in 30 years opened adjacent to Deer Valley, and it took 10 years, usage of a government permitting loophole, and cost ~$1.5 billion to build. Or you could buy Vail’s 15 major resorts (and a host of minor ones) for just over $7B in EV today. The big risk is snowfall – the current weak snow year is likely one of the main reasons the stock has fallen back down. But snowfall trends are generally up actually over the last several years, and I believe the risk to be manageable (and the Epic Pass helps smooth out revenues significantly), although it does bring a bit of random year to year variance with it.

BSD Analysis:
Vail Resorts is focusing on "resource efficiency" and premium experience upgrades in 2026, reaffirming its full-year Resort Reported EBITDA guidance of $842 million to $898 million. The 2026 investment thesis is supported by a disciplined capital plan, with plans to invest approximately $234 million to $239 million in core upgrades, including high-volume lodge remodels at Whistler Blackcomb and Beaver Creek. While season pass unit sales saw a minor 2% dip for the current cycle, sales dollars increased by 3%, demonstrating the company's persistent pricing power. Management is on track to achieve an additional $38 million in efficiency savings for fiscal 2026, part of a broader plan to reach a $100 million annualized run rate by 2027. With a quarterly dividend of $2.22 per share and an opportunistic share repurchase program, the firm offers a stable income profile for investors seeking exposure to the high-end travel and leisure market. As the company expands its European footprint, the diversification of its geography serves as a key hedge against localized weather risks.

Pitch Summary:
In the fourth quarter, Alluvial Fund purchased shares of Sylvamo Corp, a manufacturer of uncoated freesheet paper. Sylvamo has a strong history of profitability and free cash flow generation but is facing short-term headwinds from lower paper pricing, weak European demand, and the expiration of a long-term supply agreement. The company is investing in its South Carolina mills to replace lost supply and increase capacity. Industry supply reductions should support pricing. Management expects the investment program to generate a 30%+ IRR and return Sylvamo to $300 million in annual free cash flow by 2027.

BSD Analysis:
Sylvamo Corporation enters 2026 as the world’s leading uncoated freesheet producer, benefiting from a high-margin geographic mix and a disciplined capital allocation strategy. The company is successfully leveraging its "fortress" mills in Latin America and Europe to maintain a cost advantage over global competitors. For 2026, the investment thesis is anchored by the firm’s commitment to returning significant capital to shareholders through both dividends and opportunistic buybacks. Management is prioritizing the optimization of its product portfolio to counter secular declines in office paper, shifting toward high-growth segments like professional printing and packaging. Financial health remains robust, with the company achieving its long-term leverage targets and maintaining ample liquidity. While currency fluctuations in emerging markets act as a periodic variable, Sylvamo’s strong pricing power has historically allowed for effective cost pass-throughs. For value-oriented investors, the stock offers a high-yield opportunity backed by a market-leading position in an essential commodity.

Pitch Summary:
Net Lease Office Properties has been selling assets and making large cash distributions to shareholders. While achieved prices have been underwhelming, the current share price represents a large discount to the value of the remaining properties. The increased pace of dispositions gives confidence that liquidation will be substantially complete by the end of 2026. With the February cash distribution of $6.75 per share, we will have received our entire cost basis back. I continue to believe the remaining upside is attractive given how cheaply the assets were acquired.

BSD Analysis:
Net Lease Office Properties is currently in a "strategic harvesting" phase in 2026, focusing on the orderly disposition of its portfolio of single-tenant office assets. The REIT is successfully executing its mandate to maximize shareholder value through asset sales, recently closing several high-value transactions to accelerate debt repayment. For 2026, the investment case is built on the significant gap between the firm's liquidation value and its current market price. Management is prioritizing the stabilization of its remaining core assets to ensure consistent rental income while awaiting favorable market windows for divestment. While the broader office sector remains under structural pressure, NLOP's focus on long-term net leases with creditworthy tenants provides a reliable cash flow base. The company’s success in reducing its financing costs is a primary driver of its ability to return capital to shareholders via special distributions. Investors view the stock as a unique, time-bound vehicle for playing the recovery of high-quality corporate real estate valuations.

Pitch Summary:
McBride was a strong contributor despite significant volatility. UK investors repeatedly punished the shares despite management’s insistence that trading conditions were healthy. Management responded with an aggressive share repurchase plan and by reinitiating the dividend. The market welcomed these actions, and shares ended the year up 35% from the September lows. Even after the recovery, McBride trades at less than 7x this fiscal year’s estimated earnings. The company has reduced leverage to sustainable levels and is set to continue returning capital.

BSD Analysis:
McBride plc enters 2026 as a major beneficiary of the "flight to value" trend, with its private-label cleaning and hygiene products capturing significant market share from national brands. The company has successfully navigated the inflationary environment by implementing disciplined pricing and optimizing its pan-European manufacturing footprint. For 2026, the investment thesis is centered on sustained margin expansion as raw material and energy costs stabilize across the region. Management’s focus on the "Compass" strategic initiative is driving operational efficiencies and a more profitable product mix, particularly in high-demand laundry and dishwash categories. While the firm operates in a competitive retail landscape, its massive scale and deep relationships with major European discounters provide a durable moat. Financial health is improving as the company uses its robust operating cash flow to further reduce net debt and strengthen its balance sheet. For investors, McBride represents a high-quality defensive play on the resilient consumer essentials sector.

Pitch Summary:
Garrett Motion had a remarkable 2025. The company repurchased 9% of its shares outstanding, initiated a dividend, and committed to returning 75% of its free cash flow to shareholders, all of which caused the share price to double. For years, shares were held down by a large share overhang and fears of product obsolescence. The overhang has largely dissipated as hedge fund ownership declined from nearly 80% to under 10%. Meanwhile, the transition to electric vehicles is proving far slower than previously assumed, extending Garrett’s cash flow runway.

BSD Analysis:
Garrett Motion remains a premier technology leader in the automotive sector, successfully navigating the global transition toward vehicle electrification. In 2026, the company is leveraging its dominant position in turbocharging to fund its expansion into zero-emission vehicle (ZEV) technologies, including E-turbos and fuel cell compressors. The investment narrative is currently driven by the firm's robust free cash flow, which is being prioritized for aggressive share repurchases and debt reduction following its emergence from restructuring. For 2026, management expects to see continued margin expansion as its high-value light-vehicle products offset cyclicality in the commercial segment. The company’s focus on high-speed electric motors and power electronics provides a significant competitive moat as hybrid and electric powertrains become standard. While broader automotive production volatility remains a risk, Garrett’s essential role in improving engine efficiency ensures a stable revenue base. For value-oriented investors, the stock offers a compelling entry point into a mission-critical supplier with an improving capital structure.